The Role of Genetic Variation in Phenotypic Variability in Loeys–Dietz Syndrome Authors: Hussein Abdul Nabi, Luke Dreher, Jack Hartnett, Ashley Crossley, Hussein El Ghandour, Mayowa Osundiji, Hicham El Masry, Chadi Ayoub, Fadi E Shamoun, Linnea M Baudhuin, Suraiya Saleem Published: 2026 ABSTRACT AbstractBackgroundLoeys–Dietz syndrome (LDS) is a heritable connective tissue disorder caused by pathogenic variants in genes of the transforming growth factor‐β (TGF‐β) signaling pathway. Although genotype–phenotype correlations have been suggested, comprehensive comparative data across LDS subtypes remain limited. Improved understanding of these correlations is essential to guide individualized surveillance and management strategies.MethodsWe conducted a retrospective cohort study of adults with genetically confirmed LDS evaluated between 2018 and 2024 across Mayo Clinic sites. Patients with pathogenic, likely pathogenic, or suspicious variants in TGFBR1, TGFBR2, or SMAD3 were included. Clinical characteristics, physical examination findings, cardiovascular and noncardiovascular manifestations, surgical interventions, and mortality were compared across genotypes. Categorical variables were analyzed using chi‐square tests and continuous variables using parametric or nonparametric methods as appropriate.ResultsA total of 93 patients were included (29 TGFBR1, 33 TGFBR2, 31 SMAD3). Demographics and mortality did not differ significantly between groups. Patients with TGFBR1 and TGFBR2 demonstrated trends toward higher rates of ascending aortic aneurysm and aortic dissection compared with SMAD3 patients, though these differences were not statistically significant. Renal artery aneurysms were significantly more common in TGFBR1 patients (13.8%, p = 0.010). SMAD3 patients had significantly higher rates of mitral regurgitation (54.8%, p = 0.04), peripheral neuropathy (29.0%, p = 0.018), and trends toward increased atrial fibrillation and osteoarthritis. A novel association was identified between TGFBR1 variants and migraine, which was significantly more prevalent in this group (62.1%, p = 0.017). The rates of major cardiovascular surgical interventions were high and comparable across all genotypes.ConclusionDistinct genotype–phenotype associations exist among LDS subtypes. TGFBR1 and TGFBR2 variants are associated with a greater burden of aggressive vascular disease, whereas SMAD3 variants are linked to mitral valve disease, peripheral neuropathy, and osteoarthritis. We also identified a novel association between TGFBR1 genotype and migraine. These findings reinforce the importance of comprehensive genetic testing to inform personalized surveillance and management strategies in LDS.Keywords: arrhythmias, genotype–phenotype correlation, Loeys–Dietz syndrome, surgical interventions 1. Introduction Loeys–Dietz syndrome (LDS) is a connective tissue disorder (CTD) resulting from variants in genes related to the transforming growth factor beta (TGF‐β) signaling pathway, including transforming growth factor beta receptors 1 and 2 (TGFBR1 and TGFBR2), small mother against decapentaplegic 2 and 3 (SMAD2 and SMAD3), and transforming growth factor beta 2 and 3 (TGFB2 and TGFB3) [1]. The first described cases of LDS involved variants in the TGFBR1 and TGFBR2 genes, and they remain the most frequently involved genes in this syndrome [2, 3]. Initially, LDS was classified into two types depending on craniofacial (Type 1) or skin involvement (Type 2), but there are now six types of LDS based on which gene is involved (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, and SMAD2, respectively). Aberrations in these genes lead to overexpression of the TGF‐β pathway and disrupt the structural integrity and function of the extracellular matrix, leading to multisystem abnormalities [1]. There are no consensus clinical criteria for the diagnosis of LDS, and instead diagnosis is suspected in individuals with vascular, skeletal, craniofacial, cutaneous, allergic/inflammatory, ocular, and family history findings. Initially, LDS can be misdiagnosed as Marfan syndrome because of overlapping vascular, cutaneous, and skeletal manifestations. Although patients with LDS typically experience aortic dissections at younger ages and at smaller diameters compared with those with Marfan syndrome [4], there is still phenotypic overlap between these disorders and genetic testing is necessary for accurate diagnosis and risk stratification. Advances in next‐generation sequencing (NGS) technologies have facilitated the identification of novel disease‐causing genes, enabled clinical gene panel testing, and contributed to a deeper understanding of genotype–phenotype correlations in LDS [3]. Establishing these correlations is important for guiding clinical management as early studies suggest different genes and variants can result in variable phenotypic severity. Previous research has shown that TGFBR2 involvement typically results in milder craniofacial abnormalities compared with TGFBR1 [5, 6]. Additionally, SMAD3 variants are uniquely associated with osteoarthritis (and sometimes referred to as aneurysm–osteoarthritis syndrome), and along with TGFBR1/2 variants, generally correlate with more severe cardiovascular presentations compared with TGFB2 and TGFB3 [1, 2]. Patients carrying TGFBR1 and TGFBR2 variants accompanied by severe craniofacial features often experience aneurysm ruptures at younger ages and smaller aortic diameters compared with other aneurysm syndromes [5]. In this study, we sought to investigate the association between LDS genotypes and clinical characteristics, physical examination findings, and both cardiac and noncardiac clinical complications. The central aim was to further characterize genotype–phenotype correlations that may better inform patient management. 2. Methods 2.1. Study Population This retrospective study analyzed patients diagnosed with LDS between 2018 and 2024 across Mayo Clinic sites in Rochester, Arizona, and Florida. The study cohort was identified using an institutional electronic data retrieval tool, and detailed chart reviews were conducted to confirm the diagnosis. The study was approved by the Institutional Review Board (IRB) prior to data collection and informed consent was waived because of the retrospective nature of the study. Only patients with genetically confirmed LDS were included. Genetic variants were classified using a five‐tier system: pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), likely benign (LB), or benign (B), according to the 2015 American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) joint recommendations [7]. Only variants classified as P, LP, or suspicious VUS (sVUS) were included in the analysis. Patients younger than 18 years of age were excluded. Because of the small number of identified patients with TGFB2 and TGFB3 variants, these individuals were excluded from the analysis. The final study population included only patients with variants in TGFBR1, TGFBR2, and SMAD3. A comprehensive database was developed from chart reviews and included demographic information, clinical characteristics, comorbidities, and surgical history. Extracted CTD features included scoliosis or kyphosis; pectus deformities (excavatum or carinatum); joint manifestations (hypermobility, dislocations, and tendon rupture); valgus or varus deformities; pes planus; hammer toes; dermatologic features (easy bruising, soft skin); ocular findings (cataracts, exotropia, and ectopia lentis); high‐arched palate; retrognathia; dolichocephaly; malar hypoplasia; dental crowding; hypertelorism; bifid uvula; cleft palate; and down‐slanting palpebral fissures. Aneurysms and dissections involving the aorta and other vascular territories were included. Recorded surgical interventions included aortic root replacement or repair; mitral, tricuspid, and aortic valve repair or replacement; patent foramen ovale (PFO) closure; and atrial or ventricular septal defect (ASD/VSD) closure. 2.2. Study Groups Patients were divided into three groups: Group 1 included patients with variants in TGFBR1; Group 2 included patients with variants in TGFBR2, and Group 3 included patients with variants in SMAD3. 2.3. Study Outcomes The primary objective of this study was to investigate genotype–phenotype correlations by evaluating whether specific genetic variants were associated with differences in physical examination findings, aortic and nonaortic arterial complications including aneurysms and dissections, surgical interventions, and mortality. 2.4. Statistical Analysis Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS). Categorical variables are reported as frequencies and percentages (n, %) and were analyzed using chi‐square tests. Continuous variables were assessed for normality using the Shapiro–Wilk test and analyzed using independent t‐tests or Mann–Whitney U tests, as appropriate. Continuous variables are reported as mean ± standard deviation (SD) or median [interquartile range (IQR)], depending on data distribution. Statistical significance was defined as p < 0.05. 3. Results 3.1. Genetic Testing A total of 93 individuals diagnosed with LDS were identified through retrospective chart review. All diagnoses were confirmed by genetic testing. Variants were identified in TGFBR1, TGFBR2, and SMAD3. Thirty‐one patients carried SMAD3 variants, classified as sVUS (n = 1), LP (n = 18), and P variants (n = 12). There were 29 patients who had TGFBR1 variants, including 3 sVUS, 20 LP variants, and 6 P variants. Thirty‐three patients carried TGFBR2 variants, consisting of 20 LP variants and 13 P variants. Patients were categorized into three genetic groups: Group 1 (TGFBR1 variants), Group 2 (TGFBR2 variants), and Group 3 (SMAD3 variants). Figure 1 serves as the central illustration, summarizing the key findings of the study. Genotype–phenotype correlates across TGF‐β pathway genes in Loeys–Dietz syndrome (TGFBR1, TGFBR2, SMAD3). TGF‐β signaling pathway dysregulation and genotype‐specific clinical signatures in Loeys–Dietz syndrome. In this retrospective cohort of 93 adults with genetically confirmed LDS evaluated from 2018–2024 (TGFBR1 n = 29; TGFBR2 n = 33; SMAD3 n = 31), vascular, cardiac/rhythm, and extracardiovascular phenotypes differed across genotypes. TGFBR1 and TGFBR2 demonstrated a high burden of ascending aortic aneurysm (75.9% and 90.9%, respectively), with renal artery aneurysm enrichment in TGFBR1 (13.8%, p = 0.010). SMAD3 showed higher MR prevalence (54.8%, p = 0.04) and a greater burden of peripheral neuropathy (29.0%, p = 0.018), with osteoarthritis remaining prominent. Arrhythmic patterns varied, including increased atrial flutter in TGFBR2 (21.2%, p = 0.026) and a trend toward higher atrial fibrillation in SMAD3 (45.2%). A novel association was observed between TGFBR1 variants and migraine (62.1%, p = 0.017). Major cardiovascular surgical intervention rates were high across genotypes, including aortic root replacement (TGFBR1 72.4%; TGFBR2 66.7%; SMAD3 80.6%). Collectively, these data support genotype‐informed surveillance, earlier aggressive vascular imaging for TGFBR1/TGFBR2 and targeted monitoring for SMAD3‐associated mitral valve disease, arrhythmias, and peripheral neuropathy. Created in BioRender. Dreher, L. (2026) https://BioRender.com/hv1jfcu. 3.2. Demographics Demographic characteristics were similar across the three groups. Gender distribution did not differ significantly among groups (p = 0.193), with comparable representation of males and females. Racial distribution was also similar, with 82 patients (88.2%) identifying as White (p = 0.351). Mortality rates did not significantly differ between groups (p = 0.428). Death occurred in 10.3% of patients with TGFBR1 variants, 6.1% of those with TGFBR2 variants, and 16.1% of patients with SMAD3 variants. Demographic characteristics and comorbidities are summarized in Table 1. Table 1Demographic characteristics and comorbidities.FeatureGroup 1 (n = 29)Group 2 (n = 33)Group 3 (n = 31) p Gender0.193Female18 (62.1%)16 (48.5%)12 (38.7%)Male11 (37.9%)17 (51.5%)19 (61.3%)Race0.351White27 (93.1%)27 (81.8%)28 (90.3%)Non‐White2 (6.9%)6 (18.2%)3 (9.7%)Death3 (10.3%)2 (6.1%)5 (16.1%)0.428DM0 (0%)2 (6.1%)4 (12.9%)0.126HTN11 (63.6%)21 (63.6%)18 (58.1%)0.108Migraine18 (62.1%)5 (15.2%)7 (22.6%)0.017HLD5 (17.2%)12 (36.4%)14 (45.2%)0.065Stroke3 (10.3%)4 (12.1%)5 (16.1%)0.789MI0 (0%)2 (6.1%)3 (9.7%)0.246HF4 (13.8%)6 (18.2%)10 (32.3%)0.186Osteoarthritis7 (24.1%)11 (33.3%)13 (41.9%)0.344Peripheral neuropathy1 (3.4%)4 (12.1%)9 (29.0%)0.018Abbreviations: DM, diabetes mellitus; HF, heart failure; HLD, hyperlipidemia; HTN, hypertension; MI, myocardial infarction. Demographic characteristics and comorbidities. Abbreviations: DM, diabetes mellitus; HF, heart failure; HLD, hyperlipidemia; HTN, hypertension; MI, myocardial infarction. 3.3. Comorbidities Multiple comorbid conditions were evaluated across the three groups. The only comorbidity to reach a statistically significant association was migraine. Migraines were significantly more prevalent among patients with TGFBR1 variants (62.1%) compared with those carrying TGFBR2 (15.2%) or SMAD3 variants (22.6%) (p = 0.017). When stratified by sex, migraine remained more frequent among females in all three genetic groups: among TGFBR1 patients, migraine occurred in 14 of 18 females (77.8%) and 4 of 11 males (36.4%); among TGFBR2 patients, in 4 of 16 females (25.0%) and 1 of 17 males (5.9%); and among SMAD3 patients, in 5 of 12 females (41.7%) and 2 of 19 males (10.5%). In relation to risk factors for vascular disease, hypertension was most common in patients with TGFBR2 variants (63.6%), compared with 37.9% in TGFBR1 and 58.1% in SMAD3 patients; however, this difference did not reach statistical significance (p = 0.108). Diabetes mellitus was observed most frequently in the SMAD3 group (12.9%), compared with 0% in TGFBR1 and 6.1% in TGFBR2 patients (p = 0.126). Hyperlipidemia occurred most frequently in the SMAD3 group (45.2%), compared with 36.4% in TGFBR2 and 17.2% in TGFBR1 patients; this trend approached but did not reach statistical significance (p = 0.065). Body mass index (BMI) did not differ significantly among the three genetic groups (p = 0.959). The prevalence of stroke was highest among SMAD3 patients (16.7%), followed by TGFBR2 (12.1%) and TGFBR1 (10.3%) groups (p = 0.789). Heart failure (HF) was observed in 13.8% of TGFBR1, 18.2% of TGFBR2, and 32.3% of SMAD3 patients, showing a trend toward higher prevalence in SMAD3 (p = 0.186). Osteoarthritis was most prevalent among SMAD3 patients (41.9%), followed by TGFBR2 (33.3%) and TGFBR1 (24.1%) groups; however, no statistically significant difference was observed (p = 0.344). Peripheral neuropathy differed significantly across genetic groups (p = 0.018), occurring most frequently in the SMAD3 group (29.0%), compared with 3.4% in TGFBR1 and 12.1% in TGFBR2 patients. Of the 14 patients with peripheral neuropathy, only 2 had concomitant diabetes mellitus, both of whom had SMAD3 variants; these represented 2 of the 9 SMAD3 patients with peripheral neuropathy. 3.4. Physical Exam Findings Physical examination findings were compared across the three genetic groups. The prevalence of scoliosis was similar among groups, with no statistically significant difference observed (p = 0.834). Pectus deformities were more common in patients with TGFBR1 variants (51.7%), compared with 39.4% in the TGFBR2 group and 25.8% in the SMAD3 group. However, this trend did not reach significance (p = 0.119). The presence of pes planus was comparable across all groups (p = 0.460). Joint hypermobility was most frequently observed in patients with SMAD3 variants (45.2%), compared with 20.7% in TGFBR1 and 24.2% in TGFBR2 patients, approaching but not reaching statistical significance (p = 0.078). In contrast, joint dislocations were significantly more prevalent in the TGFBR2 group, affecting 29.4% of patients, compared with 6.9% in TGFBR1 and 9.7% in SMAD3 patients (p = 0.001). Cutaneous findings were comparable across all genetic groups (p = 0.963). Ophthalmologic manifestations, including cataracts and ectopia lentis, were more commonly observed in patients with SMAD3 variants (29.0%) compared with TGFBR1 (6.9%) and TGFBR2 (24.2%) patients, though this difference did not reach statistical significance (p = 0.083). Bifid uvula was most frequently identified in patients with TGFBR2 variants (21.2%), compared with 10.3% in the TGFBR1 group and 3.2% in the SMAD3 group (p = 0.080). Downslanting palpebral fissures were also more common in the TGFBR2 group (15.2%) compared with TGFBR1 (3.4%) and SMAD3 (3.2%) groups, but this trend was not statistically significant (p = 0.118). Detailed physical examination findings are summarized in Table 2. Table 2Physical examination findings.FeatureGroup 1 (n = 29)Group 2 (n = 33)Group 3 (n = 31) p Scoliosis13 (44.8%)17 (51.5%)16 (51.6%)0.834Pectus15 (51.7%)13 (39.4%)8 (25.8%)0.119Flat feet10 (34.5%)7 (21.2%)10 (32.3%)0.46Valgus/varum5 (17.2%)7 (21.9%)3 (9.7%)0.418Joint condition8 (27.6%)17 (51.5%)14 (45.2%)0.147Joint hypermobility6 (20.7%)8 (24.2%)14 (45.2%)0.078Joint dislocation2 (6.9%)13 (39.4%)3 (9.7%)0.001Skin condition7 (24.1%)7 (21.2%)7 (22.6%)0.963Eyes2 (6.9%)8 (24.2%)9 (29.0%)0.083High arched4 (13.8%)11 (33.3%)6 (19.4%)0.161Retrognathia2 (6.9%)6 (18.2%)1 (3.2%)0.107Dolichocephaly2 (6.9%)4 (12.1%)3 (9.7%)0.786Malar hypoplasia2 (6.9%)8 (24.2%)5 (16.1%)0.18Dental crowding5 (17.2%)5 (15.2%)2 (6.5%)0.41Hypertelorism4 (13.8%)4 (12.1%)3 (9.7%)0.884Bifid uvula3 (10.3%)7 (21.2%)1 (3.2%)0.08Cleft palate0 (0%)0 (0%)1 (3.2%)0.364Downslanting palpebral fissures1 (3.4%)5 (15.2%)1 (3.2%)0.118 Physical examination findings. 3.5. Cardiovascular Findings Cardiovascular manifestations were assessed across the three genetic groups. Ascending aortic aneurysms were observed in 75.9% of TGFBR1, 90.9% of TGFBR2, and 90.3% of SMAD3 patients (p = 0.164), suggesting a trend toward lower prevalence in the TGFBR1 group. Abdominal aortic aneurysms (AAA) were relatively similar across groups (27.6% TGFBR1, 27.3% TGFBR2, 29.0% SMAD3; p = 0.986). The occurrence of aortic dissections showed some genotype‐specific patterns. Type A dissections were observed in 27.6% of TGFBR1, 12.1% of TGFBR2, and 22.6% of SMAD3 patients (p = 0.301), whereas type B dissections were seen in 27.6% of TGFBR1, 9.1% of TGFBR2, and 16.1% of SMAD3 patients (p = 0.154). Although these differences were not statistically significant, they suggest a trend toward higher dissection rates in the TGFBR1 group for both Type A and B dissections. Overall dissection presence occurred in 27.6% of TGFBR1, 18.2% of TGFBR2, and 32.3% of SMAD3 patients (p = 0.422), indicating a slightly higher burden in SMAD3 and TGFBR1 patients. Other arterial dissections, including vertebral, carotid, coronary, innominate, iliac, subclavian, cerebral, splenic, and mesenteric arteries, were uncommon and did not differ significantly across groups (all p > 0.05). Regarding aneurysm distribution, most vascular territories were similarly affected across genotypes, except for renal artery aneurysms, which were significantly more frequent in TGFBR1 patients (13.8%) compared with 0% in TGFBR2 and SMAD3 groups (p = 0.010). Detailed aneurysm and dissection distributions are presented in Table 3. Table 3Aneurysm and dissection distributions.FeatureGroup 1 (n = 29)Group 2 (n = 33)Group 3 (n = 31) p Ascending aorta aneurysm22 (75.9%)30 (90.9%)28 (90.3%)0.164Abdominal aortic aneurysm8 (27.6%)9 (27.3%)9 (29.0%)0.986 Type A8 (27.6%)4 (12.1%)7 (22.6%)0.301 Type B8 (27.6%)3 (9.1%)5 (16.1%)0.154Dissection presence8 (27.6%)6 (18.2%)10 (32.3%)0.422 Vertebral artery dissection1 (3.4%)3 (9.1%)4 (12.9%)0.423 Carotid artery dissection5 (17.2%)1 (3.0%)4 (12.9%)0.176 Renal artery dissection1 (3.4%)0 (0%)0 (0%)0.328 Iliac artery dissection1 (3.4%)1 (3.0%)1 (3.2%)0.996 Coronary artery dissection2 (6.9%)0 (0%)2 (6.5%)0.316 Innominate artery dissection2 (6.9%)1 (3.0%)1 (3.2%)0.708Aneurysm presence17 (58.6%)16 (48.5%)19 (61.3%)0.552 Carotid artery aneurysm5 (17.2%)4 (12.1%)4 (12.9%)0.826 Vertebral artery aneurysm1 (3.4%)1 (3.0%)1 (3.2%)0.996 Splenic artery aneurysm1 (3.4%)2 (6.1%)3 (9.7%)0.614 Mesenteric artery aneurysm6 (20.7%)3 (9.1%)3 (9.7%)0.32 Renal artery aneurysm4 (13.8%)0 (0%)0 (0%)0.01 Iliac artery aneurysm5 (17.2%)4 (12.1%)10 (32.3%)0.119 Subclavian artery aneurysm2 (6.9%)3 (9.1%)2 (6.5%)0.912 Cerebral artery aneurysm7 (24.1%)8 (24.2%)9 (29.0%)0.881 Coronary artery aneurysm5 (17.2%)1 (3.0%)3 (9.7%)0.168 Aneurysm and dissection distributions. 3.6. Valvular Abnormalities and Cardiovascular Surgery Regarding valvular abnormalities, mitral regurgitation (MR) was present in 24.1% of TGFBR1, 33.3% of TGFBR2, and 54.8% of SMAD3 patients, showing a statistically significant difference between groups (p = 0.04), with a trend toward more MR in SMAD3 patients. Mitral valve prolapse (MVP) was observed in 24.1% of TGFBR1, 45.5% of TGFBR2, and 32.3% of SMAD3 patients (p = 0.202). Tricuspid regurgitation (TR) occurred in 10.3% of TGFBR1, 12.1% of TGFBR2, and 3.2% of SMAD3 patients (p = 0.412), whereas bicuspid aortic valve was rare, observed in 10.3%, 9.1%, and 6.5% of patients across groups, respectively (p = 0.859). Aortic regurgitation was present in roughly half of patients in each group (51.7% TGFBR1, 45.5% TGFBR2, 51.6% SMAD3; p = 0.848). Mitral valve replacement (MVR) was performed in 6.9% of TGFBR1, 9.1% of TGFBR2, and 12.9% of SMAD3 patients (p = 0.727), whereas tricuspid valve replacement (TVR) was less frequent, occurring in 17.2% of TGFBR1, 6.1% of TGFBR2, and 3.2% of SMAD3 patients, showing a trend toward more TVR in TGFBR1 (p = 0.125). Aortic valve replacement (AVR) was performed in 44.8% of TGFBR1, 39.4% of TGFBR2, and 54.8% of SMAD3 patients (p = 0.457), and aortic root replacement (ARR) was the most common intervention overall, observed in 72.4% of TGFBR1, 66.7% of TGFBR2, and 80.6% of SMAD3 patients (p = 0.449). Additional procedures, including ASD, VSD, and PFO closure, were performed in 27.6% of TGFBR1, 15.2% of TGFBR2, and 16.1% of SMAD3 patients (p = 0.399). Overall, although trends in valvular abnormalities were identified, particularly higher rates of MR in SMAD3, differences in rates of most surgical interventions and valvular abnormalities did not reach statistical significance. Detailed cardiovascular surgery and valvular abnormality distributions are presented in Table 4. Table 4Cardiovascular surgery and valvular abnormality distributions.VariableGroup 1 (n = 29)Group 2 (n = 33)Group 3 (n = 31) p MR7 (24.1%)11 (33.3%)17 (54.8%)0.04TR3 (10.3%)4 (12.1%)1 (3.2%)0.412Bicuspid aortic valve3 (10.3%)3 (9.1%)2 (6.5%)0.859MVP7 (24.1%)15 (45.5%)10 (32.3%)0.202Aortic regurgitation15 (51.7%)15 (45.5%)16 (51.6%)0.848MVR2 (6.9%)3 (9.1%)4 (12.9%)0.727TVR5 (17.2%)2 (6.1%)1 (3.2%)0.125AVR13 (44.8%)13 (39.4%)17 (54.8%)0.457ARR21 (72.4%)22 (66.7%)25 (80.6%)0.449ASD/VSD/PFO Closure8 (27.6%)5 (15.2%)5 (16.1%)0.399Abbreviations: ARR, aortic root replacement; ASD, atrial septal defect; AVR, aortic valve replacement; MR, mitral regurgitation; MVP, mitral valve prolapse; MVR, mitral valve replacement; PFO, patent foramen ovale; TR, tricuspid regurgitation; TVR, tricuspid valve replacement; VSD, ventricular septal defect. Cardiovascular surgery and valvular abnormality distributions. Abbreviations: ARR, aortic root replacement; ASD, atrial septal defect; AVR, aortic valve replacement; MR, mitral regurgitation; MVP, mitral valve prolapse; MVR, mitral valve replacement; PFO, patent foramen ovale; TR, tricuspid regurgitation; TVR, tricuspid valve replacement; VSD, ventricular septal defect. 3.7. Cardiac Arrhythmias The prevalence of arrhythmias varied across the three groups. AF was present in 27.6% of TGFBR1, 24.2% of TGFBR2, and 45.2% of SMAD3 patients, showing a trend toward higher AF prevalence in SMAD3 (p = 0.164). Atrial flutter was more frequent in TGFBR2 (21.2%) compared with TGFBR1 (0%) and SMAD3 (9.7%), reaching statistical significance (p = 0.026), whereas the combined “category one” arrhythmia group occurred in 27.6%, 30.3%, and 45.2% of patients, respectively (p = 0.296). Supraventricular tachycardia (SVT) was observed in 24.1% of TGFBR1, 9.1% of TGFBR2, and 19.4% of SMAD3 patients (p = 0.272), whereas ventricular tachycardia (VT) occurred in 10.3%, 18.2%, and 22.6% across groups (p = 0.447). Ventricular fibrillation or VT (VF/VF tach) was most common in SMAD3 (29.0%), compared with 10.3% in TGFBR1 and 21.2% in TGFBR2, showing a trend toward increased risk in SMAD3 (p = 0.198). Overall, atrial flutter and VF/VF showed notable differences among groups, whereas other arrhythmias demonstrated trends without reaching statistical significance. Detailed arrhythmia distributions are presented in Table 5. Table 5Arrhythmia distributions.ArrhythmiaGroup 1 (n = 29)Group 2 (n = 33)Group 3 (n = 31) p Atrial fibrillation8 (27.6%)8 (24.2%)14 (45.2%)0.164Atrial flutter0 (0.0%)7 (21.2%)3 (9.7%)0.026Category onea 8 (27.6%)10 (30.3%)14 (45.2%)0.296SVT7 (24.1%)3 (9.1%)6 (19.4%)0.272VT3 (10.3%)6 (18.2%)7 (22.6%)0.447VF/VT3 (10.3%)7 (21.2%)9 (29.0%)0.198Abbreviations: SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia. aCategory one refers to patients having atrial arrhythmia (atrial fibrillation or atrial flutter). Arrhythmia distributions. Abbreviations: SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia. aCategory one refers to patients having atrial arrhythmia (atrial fibrillation or atrial flutter). 4. Discussion In this study genotype–phenotype correlations were identified among 93 LDS patients, particularly highlighting the significance of gene‐specific differences (TGFBR1, TGFBR2, SMAD3). Overall, in keeping with prior publications, our data suggest that TGFBR1 and TGFBR2 patients experience more aortic and nonaortic vascular complications in comparison to SMAD3 patients. Although vascular disease was less common, SMAD3 patients tended to experience more osteoarthritis and MR. There was no difference in mortality between TGFBR1, TGFBR2, and SMAD3 LDS patients. Among LDS types, TGFBR1, TGFBR2, and SMAD3 mutations drive more aggressive phenotypes with earlier vascular disease compared with milder TGFB1 and TGFB2 mutations [1]. Although TGFB1 and TGFB2 groups were not studied because of low numbers, lower mortality among these patients would be expected. Although not statistically significant, ascending aortic aneurysms were more frequently seen in TGFBR2 and SMAD3 patients compared with the TGFBR1 cohort (75.9% vs. 90.9% vs. 90.3%, p = 0.164). Similarly, both Type A and Type B aortic dissections were numerically most common in the TGFBR1 group followed by SMAD3 then TGFBR2 (Type A: 27.6% vs. 12.1% vs. 22.6%, Type B: 27.6% vs. 9.1% vs. 16.1%). Previous literature has documented the propensity of TGFBR1 and TGFBR2 variants for early‐onset severe vascular events, even at smaller aortic dimensions [5]. In larger registries, over 40% of patients with TGFBR1/2 variants experienced aortic dissections, with some dissections occurring at diameters below 45 mm, especially in female TGFBR2 carriers [3]. Our findings correspond well with the current understanding of LDS pathophysiology, whereby loss of function mutations in the TGF‐β receptor genes lead to paradoxical activation of TGF‐β signaling. Numerous different hypotheses regarding the underlying mechanism for paradoxical activity have been proposed including loss of negative feedback leading to enhanced pathway activity and paracrine TGF‐β signaling [1]. Regardless, repeated studies have demonstrated a high propensity for early‐onset aortic aneurysms and dissections in TGFBR1 and TGFBR2 patients [3, 6]. In comparison to prior data, our cohort showed numerically lower rates of aortic aneurysms and dissections among SMAD3 patients. An international SMAD3 cohort (Montalcino Aortic Consortium) reported aortic events in 37% of their cases, in which 70% of those were dissections [7]. The median age of onset of aortic event in this cohort was 47 years, notably higher than TGFBR1 and TGFBR2 patients in other studies. Vascular and valvular surgery was required at similar rates across the three genetic subtypes. Although aortic valve replacement was necessary in approximately half of the patients in each cohort, aortic root replacement was required in almost 72.4% of TGFBR1 patients, 66.7% of TGFBR2 patients, and 80.6% of SMAD3 patients. The high rate of aortic surgery has been well established among TGFBR1 and TGFBR2 patients. In a seminal study of 90 TGFBR1 or TGFBR2 patients published in the New England Journal of Medicine, 59 patients required vascular surgery involving the aorta or its major branches and the median age of first surgery was 16.9 years [5]. Although rates of aortic aneurysm and dissection were lower, aortic root replacement rates in our SMAD3 group are higher than previously reported. This is in keeping with longitudinal data which indicate SMAD3 patients often require prophylactic aortic surgery—in one series, 50% of patients underwent elective root replacement within approximately 10 years of diagnosis [8]. Our findings are broadly consistent with previous studies linking SMAD3 variants to vascular phenotypes, likely due to impaired vascular integrity stemming from abnormal vascular smooth muscle cell function and disrupted extracellular matrix remodeling [9–11]. Aortas with SMAD3 variants show paradoxical TGF‐B activation, where impaired SMAD signaling results in ligand overexpression and excessive noncanonical pathway activity, factors that likely contribute to the arterial wall vulnerability and aneurysm formation [1, 7]. Our data also supports the association between SMAD3 mutations and mitral valve disease. Although early‐onset ascending aortic disease predominates in TGFBR1 and TGFBR2 LDS, mitral valve disease is often the most common cardiovascular manifestation among SMAD3 patients. In one study, 84% of SMAD3 patients had a cardiovascular abnormality −58% patients hadMVP followed by 42% with aortic disease [12]. Mitral valve disease rates have varied in prior publications from 19% to 58% [7, 12]. Among SMAD3 patients in our study, 54.8% had MR compared with 24.1% and 33.3% among TGFBR1 and TGFBR2 patients, respectively (p = 0.04). Although not statistically significant, higher rates of MVR were also observed in the SMAD3 group (12.9% in SMAD3 vs. 6.9% in TGFBR1 and 9.1% in TGFBR2). In keeping with the propensity for MR, atrial fibrillation was most common among SMAD3 patients (45.2% in SMAD3 vs. 27.6% in TGFBR1 and 24.2% in TGFBR2). A previous study in patients with LDS demonstrated an association between MR and increased LAVI, which may contribute to the increased risk of AF observed in this population [13]. Thus, the higher burden of AF among SMAD3 patients may, at least in part, reflect their greater prevalence of mitral valve disease rather than a direct genotype‐specific association. TGFBR1, TGFBR2 and SMAD3 mutations all affect downstream activity of the canonical and noncanonical TGF‐β pathway. From a surface level it is unclear why SMAD3 mutations lead to more mitral valve disease. Further research into the differential mechanistic effects of SMAD3 mutations on the TGF‐β pathway is required to untangle its predisposition for mitral valve involvement. Previously named aneurysms‐osteoarthritis syndrome, the association between SMAD3 mutations and early‐onset osteoarthritis has been well established [9]. Prior publications have reported osteoarthritis rates of up to 92% [12]. Notably, osteoarthritis tends to develop at a young age and often involves multiple unusual joints [9, 12]. Although not statistically significant, osteoarthritis was more common in our SMAD3 group compared with TGFBR1 and TGFBR2 patients (41.9% vs. 24.1% vs. 33.3%, p = 0.344). However, the osteoarthritis rate in our SMAD3 group (41.9%) is lower than reported in the existing literature. There was a significant difference in peripheral neuropathy rates across the groups (p = 0.018). Peripheral neuropathy was found most frequently in the SMAD3 group (29.0%) compared with TGFBR1 patients (3.4%) and TGFBR2 patients (12.1%). Early studies of families with SMAD3 mutations, even prior to it being classified as a form of LDS, reported peripheral neuropathy as a frequent manifestation [14]. The form of neuropathy described is an axonal and sensory neuropathy similar to that of Type II Charcot–Marie–Tooth. Although the links between SMAD3 and peripheral neuropathy are well characterized, no association between TGFBR1, TGFBR2 mutations, and peripheral neuropathy has been established to date. Our data are in keeping with this. The higher prevalence of migraine among TGFBR1 patients represents a novel genotype–phenotype association. Migraine was significantly more prevalent (p = 0.017) among TGFBR1 patients (62.1%) compared with TGFBR2 patients (15.2%) or SMAD3 patients (22.6%). When stratified by sex, migraine remained more frequent among females in all three genetic groups. Thus, the higher prevalence of migraine in the TGFBR1 group was not solely attributable to the female predominance in that group, although females accounted for the majority of affected patients. No prior studies have identified a link between LDS genotype and migraine. TGFBR1 mutations are known to cause nonaortic arterial disease, including aneurysms and tortuosity [15, 16]. Intracranial involvement could theoretically precipitate chronic headache in this cohort compared with other genotypes. Although a recent study did determine that 75% of all nonaortic arterial disease in LDS patients involves the arch vessels or cerebral circulation, the authors did not identify any significant variation in the rate of nonaortic arterial disease between genetic subtypes [17]. Another plausible mechanism for the propensity for headache among TGFBR1 patients is increased rates of cervical spinal disease. Although our data did not identify any significant differences in rates of skeletal deformities between genotypes, prior publications report increased rates of cervical spinal instability in TGFBR1 patients [16, 18]. Overall, our data are in keeping with prior literature that there are strong genotype–phenotype associations among different LDS subtypes. This emphasizes the value of comprehensive genetic testing in patients with LDS to aid individualized surveillance and management based on genotype. 4.1. Limitations This study has several limitations. Firstly, it involved patients from multiple Mayo Clinic sites within a single tertiary referral healthcare system, potentially restricting the generalizability of the results to broader patient populations with differing management practices and protocols. Because this cohort was derived from a multicenter tertiary referral system rather than a population‐based or genetic registry, it may preferentially represent patients with more complex or severe disease, and differences in referral patterns and genetic ascertainment may therefore result in a distribution of genetic variants that differs from that reported in the general LDS population. Additionally, despite thorough validation efforts using ICD‐10 coding and manual database reviews, there remains the possibility of inaccuracies or misclassification of clinical conditions and comorbidities. Finally, the relatively modest sample size in the setting of this rare, albeit clinically important condition limits statistical power, potentially affecting the ability to detect significant differences among the genetic subtypes. 5. Conclusion The phenotypic variability across genetic subtypes underscores the necessity of individualized surveillance strategies in patients with LDS. TGFBR1 and TGFBR2 patients may benefit from earlier and more intensive imaging monitoring for early‐onset aggressive vascular disease, whereas SMAD3 patients require close attention to mitral valvular disease, peripheral neuropathy, and osteoarthritis. In addition, we report a novel association between TGFBR1 genotype and migraine. Future studies investigating specific genetic variants in larger cohorts are needed to improve our understanding of underlying mechanisms and refine personalized clinical management strategies for patients with LDS. Author Contributions Hussein Abdul Nabi and Luke Dreher contributed equally to this work and share first authorship. Funding No funding was received for this manuscript. Ethics Statement This study was approved by the Mayo Clinic Institutional Review Board (IRB). Conflicts of Interest The authors declare no conflicts of interest. Nabi, Hussein Abdul , Dreher, Luke , Hartnett, Jack , Crossley, Ashley , El Ghandour, Hussein , Osundiji, Mayowa , El Masry, Hicham , Ayoub, Chadi , Shamoun, Fadi E. , Baudhuin, Linnea M. , The Role of Genetic Variation in Phenotypic Variability in Loeys–Dietz Syndrome, Human Mutation, 2026, 2861205, 10 pages, 2026. 10.1155/humu/2861205 Academic Editor: Suraiya Saleem Contributor Information Fadi E. Shamoun, Email: shamoun.fadi@mayo.edu. Suraiya Saleem, Email: ssaleem@wiley.com. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.